Akeso’s Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer’s Disease Clinical Trials in China
HONG KONG, Nov. 17, 2025 /PRNewswire/ — Akeso, Inc. (HKEX: 9926.HK) announced that its AK152, a novel bispecific antibody targeting both amyloid-beta (Aβ) and blood-brain barrier (BBB) expressed receptor, has been granted appr… อ่านเพิ่ม




















